NOBAZIT®
- Registration number:ЛП-003508
- International non-proprietary name:enisamium iodide
- Pharmaceutical form:film-coated tablets
- Pharmacotherapeutic group:antiviral agent
- Dosage form:tablets 250 mg No. 10
NOBAZIT® is an antiviral agent.
• It inhibits the activity of viruses causing influenza and acute respiratory viral infections
• It increases body resistance to viral infections
• It contributes to reduction of the disease duration
- Indications for use:
- Treatment of influenza and other acute respiratory viral infections, including that in combination therapy
- Method of administration and posology:
- The treatment should be started when the first disease signs appear. If there is no improvement after 3 days of treatment or the symptoms aggravate, or new symptoms occur, one should consult the doctor.
-
- Nobazit® is taken orally after the meal without chewing; 0.5 g 3 times daily.
- Maximal single dose is 1 g, and daily dose is 2 g.
- Recommended treatment course is 5-7 days.
- Manufacturer
- "Moskhimfarmpreparaty" im. N. A. Semashko" LLC
We recommend
-
Enterosorbent.
-
Antifungal agent
-
-
NOBAZIT®
-
Potassium and magnesium preparation
-
Antifungal agents
-
Antimicrobial agent
-
Metabolic agent
-
Antimicrobial and antiprotozoal agent.
-
Antiviral drug
-
Calcium channel blocker
-
Antifungal agent
-
Analgesic agent
-
Combination antimicrobial agent
-
Combination drug
-
Non-steroidal anti-inflammatory drug (NSAID)
-
Combination drug
-
-
Spasmolytic agent
-
-
Antimicrobial agent
-
Antimicrobial agent
-
Vitamin preparation
-
-
Coronary dilating drug
-
-
antiviral agent, aciclovir
-
-
Antimicrobial agent
-
Antiepileptic agent
-
-
Antimicrobial agent
-
Sedating medication
-
Enzyme product
-
Antimicrobial and antiprotozoal agent